Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Non-Current Deffered Revenue (2018 - 2025)

Historic Non-Current Deffered Revenue for 10x Genomics (TXG) over the last 6 years, with Q4 2025 value amounting to $10.5 million.

  • 10x Genomics' Non-Current Deffered Revenue fell 1607.93% to $10.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.5 million, marking a year-over-year decrease of 1607.93%. This contributed to the annual value of $10.5 million for FY2025, which is 1607.93% down from last year.
  • As of Q4 2025, 10x Genomics' Non-Current Deffered Revenue stood at $10.5 million, which was down 1607.93% from $10.9 million recorded in Q3 2025.
  • Over the past 5 years, 10x Genomics' Non-Current Deffered Revenue peaked at $12.6 million during Q1 2025, and registered a low of $3.2 million during Q4 2022.
  • Moreover, its 4-year median value for Non-Current Deffered Revenue was $11.1 million (2025), whereas its average is $10.3 million.
  • In the last 5 years, 10x Genomics' Non-Current Deffered Revenue surged by 17848.34% in 2023 and then plummeted by 1607.93% in 2025.
  • Quarter analysis of 4 years shows 10x Genomics' Non-Current Deffered Revenue stood at $3.2 million in 2022, then skyrocketed by 178.48% to $8.8 million in 2023, then skyrocketed by 41.97% to $12.5 million in 2024, then dropped by 16.08% to $10.5 million in 2025.
  • Its last three reported values are $10.5 million in Q4 2025, $10.9 million for Q3 2025, and $11.3 million during Q2 2025.